Home Newsfeeds Morgan Stanley Maintains Overweight on S&P Global, Lowers Price Target to $398

Morgan Stanley Maintains Overweight on S&P Global, Lowers Price Target to $398

Morgan Stanley analyst Toni Kaplan maintains S&P Global (NYSE:SPGI) with a Overweight and lowers the price target from $401 to $398.

byBenzinga Newsdesk

July 7, 2022

1 minute read

Morgan Stanley analyst Toni Kaplan maintains S&P Global (NYSE:SPGI) with a Overweight and lowers the price target from $401 to $398.

Why NuScale Power Stock Is Trading Higher Today

By Shivani Kumaresan

May 22, 9:09 AM

On the eve of the G7 Leaders Summit in Hiroshima, Japan, the Biden Administration, along with multinational partners have announced…

SMR

Goldman Sachs Maintains Buy on Moderna, Raises Price Target to $296

By Benzinga Newsdesk

October 13, 10:00 AM

Goldman Sachs analyst Salveen Richter maintains Moderna (NASDAQ:MRNA) with a Buy and raises the price target from $290 to $296.

MRNA

FDA
News

Arbutus Biopharma Provides Update On The Phase 2A Combination Trial With AB-729 And A Capsid Inhibitor

By Benzinga Newsdesk

July 20, 4:13 PM

Arbutus Biopharma Corporation (NASDAQ:ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that

ABUS

Marriott Picks OpenTable As Preferred Restaurant Technology Provider

By Shivani Kumaresan

July 26, 2:22 PM

Booking Holdings Inc (NASDAQ:BKNG) owned OpenTable has signed a global agreement to become a preferred restaurant technology provider to Marriott International Inc (NASDAQ:MAR). OpenTable…

BKNG

Morgan Stanley Maintains Overweight on S&P Global, Lowers Price Target to $398

Related Posts

Why NuScale Power Stock Is Trading Higher Today

Goldman Sachs Maintains Buy on Moderna, Raises Price Target to $296

Arbutus Biopharma Provides Update On The Phase 2A Combination Trial With AB-729 And A Capsid Inhibitor

Marriott Picks OpenTable As Preferred Restaurant Technology Provider